Here's the press release. I got a kick out of the third paragraph. How many ways can you say "correcting one-product deficiency"??
Transcend Therapeutics Promotes Two Executives and Appoints Four To
Development Team
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 1, 1997--TRANSCEND THERAPEUTICS,
INC. (NASDAQ: TSND
- news) today announced the promotion of John J. Whalen, M.D., Senior
Vice President and Chief Scientific Officer (CSO) to
the newly created position of Executive Vice President. Dr. Whalen will
continue to serve as the company's CSO. B. Nicholas
Harvey, Chief Financial Officer and Secretary of the Board, was promoted
to the newly created position of Senior Vice
President, Finance.
The company also announced the appointment of Harvey Dickstein, M.D. as
Vice President Clinical Research, John M. Guley
as Director Regulatory Affairs, Theodore E. Maione, Ph.D. as Senior
Director Preclinical and Waldemar Palaitis, Ph.D. as
Senior Director Chemistry and Manufacturing. All appointments and
promotions are effective immediately.
Commenting on today's announcement, Hector J. Gomez, M.D., Ph.D.,
President & CEO of Transcend Therapeutics, stated,
''Transcend's strategic objective is to bring Procysteine r to
commercialization while continuing to enhance our product
portfolio with other promising, late-stage critical care products. To
that end, we have assembled a team of development
specialists who bring to the company a wealth of preclinical, clinical,
regulatory, quality assurance and business development
experience. We are pleased to add these distinguished individuals to our
team as we strive to strengthen our product pipeline.
Going forward, we believe their vision and experience will assist us in
advancing our existing products through the FDA
approval process and helping identify new product opportunities in the
critical care market.''
Dr. Gomez, added, ''I am also pleased to announce the promotions of Dr.
Whalen and Mr. Harvey. Both have contributed
significantly to the growth of our company and played a major role in
the achievement of two critical milestones for 1997, the
collaboration with Boehringer Ingelheim and the Initial Public
Offering.''
Dr. Dickstein was most recently Vice President, Medical Affairs for
Warner-Lambert, Worldwide Consumer Products
Healthcare Research and Development. At Warner-Lambert, Dr. Dickstein
was responsible for drug safety surveillance,
pharmacology/toxicology, strategic planning and FDA relations. Prior to
that he was Vice President, Medical Affairs for
Parke-Davis where he completed a major investigation of Accupril in
hypertension with 2,400 investigators and 25,000
patients. Throughout his career, which has also included positions at
E.R. Squibb, Johnson & Johnson, Abbott and Baxter, Dr.
Dickstein has been instrumental in driving products through the FDA
approval process. From 1983 to 1985, Dr. Dickstein
worked for the FDA as a Supervisory Medical Officer for surgical,
anesthetic and dental products. He received his M.D. from
Tufts University School of Medicine.
John Guley joined Transcend Therapeutics from Repligen Corporation where
he served as Director of Regulatory Affairs and
supervised the regulatory function in support of new and biological
products under development. Prior to Repligen, Mr. Guley
was Director of Regulatory Affairs at Alpha Therapeutic Corporation
where he planned, organized and directed the Biological
Division Regulatory Affairs department which supported products totaling
over $220 million in annual sales. While at Alpha
Therapeutics he also monitored regulatory compliance of the company's
clinical testing laboratory with over 2.5 million samples
tested annually. Mr. Guley holds a B.S. in Chemistry and is completing
his Masters Degree in Biology at Harvard University.
Dr. Maione spent twelve years at Repligen Corporation where he
spearheaded the company's PF4 program for Heparin
reversal. Over the years he established strategic research and
development plans for new biotech-based products, and
managed the clinical and regulatory aspects of active Repligen
development programs. Dr. Maione's work has been awarded
eight patents, with several patents pending. Dr. Maione holds a Ph.D. in
Plant Physiology/Biochemistry from Cornell University.
Dr. Palaitis has extensive experience in pharmaceutical operations with
emphasis on Quality Assurance and Quality Control,
Regulatory Affairs and Research and Development. He has served as
Director of Analytical Methods Development for both
Depotech, Inc. and Liposome Company. Prior to these positions, he was
Manager of Analytical Research for Merck & Co.'s
Chemical Manufacturing Division. Dr. Palaitis holds a Ph.D. in Physical
Organic Chemistry from the University of Pennsylvania. (snip) |
